Citi analyst Patrick Donnelly views Danaher’s (DHR) acquisition of Abcam (ABCM) favorably, saying the deal allows the company to enter into the high-growth, higher margin protein consumables market. By the expected deal close, Danaher should be at one-times net leverage, well below the requirements of maintaining an investment grade rating, the analyst tells investors in a research note. The firm affirms a Buy rating on the shares with a $300 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DHR: